Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection

Experimental Eye Research

Volumn 110, Issue , 2013, Pages 50-54

  Costagliola, Ciro ^a   Daniele, Aurora ^b   dell'Omo, Roberto ^a   Romano, Mario R ^a   Aceto, Fabiana ^a   Agnifili, Luca ^c   Semeraro, Francesco ^d   Porcellini, Antonio ^e  

^a UNIVERSITY OF MOLISE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Adiponectin; Aqueous humor; Diabetic macular edema; Proliferative diabetic retinopathy; Vascular endothelial growth factor

Indexed keywords

ADIPONECTIN; BEVACIZUMAB; VASCULOTROPIN;

ADULT; ANGIOGRAPHY; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FOVEA; TONOMETRY; VISUAL ACUITY;

ADIPONECTIN; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84875660152     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.02.004     Document Type: Article

References (40)

1. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994, 331:1480-1487.
2. Arevalo J.F., Wu L., Sanchez J.G., Maia M., Saravia M.J., Fernandez C.F., Evans T. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009, 23:117-123.
3. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J., Wendel R., Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006, 113:1695-1705.
4. Cai J., Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002, 16:242-260.
5. Caldwell R.B., Bartoli M., Behzadian M.A., El-Remessy A.E., Al-Shabrawey M., Platt D.H., Caldwell R.W. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab. Res. Rev. 2003, 19:442-455.
6. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003, 278:45021-45026.
7. Cheung C.M., Vania M., Ang M., Chee S.P., Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol. Vis. 2012, 18:830-837.
8. Cunha-Vaz J., Faria de Abreu J.R., Campos A.J. Early breakdown of the blood-retinal barrier in diabetes. Br. J. Ophthalmol. 1975, 59:649-656.
9. Daniele A., Cammarata R., Fasullo M., Nerone G., Finamore F., D'Andrea M., Pilla F., Oriani G. Analysis of adiponectin gene and comparison of its expression in two different pig breeds. Obesity 2008, 16:1869-1874.
10. ETDRS report no.19.Early Treatment Diabetic Retinopathy Study Research Group Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. Arch. Ophthalmol. 1995, 113:1144-1155.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl. 1):S5-S20.
12. Ferrara N., Mass R.D., Campa C., Kim R. Targeting VEGF-A to treat cancer and age- related macular degeneration. Annu. Rev. Med. 2007, 58:491-504.
13. Frystyk J., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005, 48:1911-1918.
14. Fukumura D., Ushiyama A., Duda D.G., Xu L., Tam J., Krishna V., Chatterjee K., Garkavtsev I., Jain R.K. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ. Res. 2003, 93:e88-97.
15. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 2009, 94:3171-3182.
16. Goldstein B.J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 2004, 89:2563-2568.
17. Han X., Guo C., Li Y., Hui Y. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α. Mol. Vis. 2012, 18:1-9.
18. Higuchi A., Ohashi K., Kihara S., Walsh K., Ouchi N. Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression. Circ. Res. 2009, 104:1058-1065.
19. Holekamp N.M., Bouck N., Volpert O. Pigment epithelium derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age related macular degeneration. Am. J. Ophthalmol. 2002, 134:220-227.
20. Kakinoki M., Sawada O., Sawada T., Saishin Y., Kawamura H., Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest. Ophthalmol. Vis. Sci. 2012, 53:5877-5880.
21. Kato K., Osawa H., Ochi M., Kusunoki Y., Ebisui O., Ohno K., Ohashi J., Shimizu I., Fujii Y., Tanimoto M., Makino H. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin. Endocrinol. 2008, 68:442-449.
22. Kougias P., Chai H., Lin P.H., Yao Q., Lumsden A.B., Chen C. Effects of adipocyte- derived cytokines on endothelial functions: implication of vascular disease. J. Surg. Res. 2005, 126:121-129.
23. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., Eto K., Yamashita T., Kamon J., Satoh H., Yano W., Froguel P., Nagai R., Kimura S., Kadowaki T., Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002, 277:25863-25866.
24. Kvanta A., Algvere P.V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 1996, 37:1929-1934.
25. Mao D., Peng H., Li Q., Wang J., Li P., Hu K., Zhang X., Lei B. Aqueous humor and plasma adiponectin levels in proliferative diabetic retinopathy patients. Curr. Eye Res. 2012, 37:803-808.
26. Matsuyama K., Ogata N., Jo N., Shima C., Matsuoka M., Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn. J. Ophthalmol. 2009, 53:243-248.
27. Misu H., Ishikura K., Kurita S., Takeshita Y., Ota T., Saito Y., Takahashi K., Kaneko S., Takamura T. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One 2012, 7:e34952.
28. Mohan N., Monickaraj F., Balasubramanyam M., Rema M., Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J. Diabetes Complications 2012, 26:435-441.
29. Rangasamy S., McGuire P.G., Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr. J. Ophthalmol. 2012, 19:52-59.
30. ®) for treatment of diabetic macular oedema: a morphologic and functional study. Br. J. Clin. Pharmacol. 2012, 74:940-946.
31. Salam A., Mathew R., Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 2011, 89:405-411.
32. Sawada O., Kawamura H., Kakinoki M., Sawada T., Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch. Ophthalmol. 2007, 125:1363-1366.
33. Semeraro F., Parrinello G., Cancarini A., Pasquini L., Zarra E., Cimino A., Cancarini G., Valentini U., Costagliola C. Predicting the risk of diabetic retinopathy in type 2 diabetic patients. J. Diabetes Complications 2011, 25:292-297.
34. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
35. Tolentino M.J., Miller J.W., Gragoudas E.S., Chatzistefanou K., Ferrara N., Adamis A.P. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch. Ophthalmol. 1996, 114:964-970.
36. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., Suzuma I., Ohashi H., Ojima T., Murakami T., Kobayashi T., Masuda S., Nagao M., Yoshimura N., Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 2005, 353:782-792.
37. Watkins P.J. Retinopathy. Br. Med. J. 2003, 326:924-926.
38. Wells J.A., Murthy R., Chibber R., Nunn A., Molinatti P.A., Kohner E.M., Gregor Z.J. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br. J. Ophthalmol. 1996, 80:363-366.
39. Woo Y.C., Tso A.W., Xu A., Law L.S., Fong C.H., Lam T.H., Lo S.V., Wat N.M., Cheung B.M., Lam K.S. Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction. PLoS One 2012, 7:e36868.
40. Yilmaz M.I., Sonmez A., Acikel C., Celik T., Bingol N., Pinar M., Bayraktar Z., Ozata M. Adiponectin may play a part in the pathogenesis of diabetic retinopathy. Eur. J. Endocrinol. 2004, 151:135-140.